Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.60 |
| ▸ | NOS1 | P29475 | 1/20 | 0.60 |
| ▸ | NOS2 | P35228 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 14/20 | 0.44 |
| ▸ | BCHE | P06276 | 9/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29770726 | 0.96 | NOS3 (0.55) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL4928360 | 0.96 | NOS3 (0.55) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL2624108 | 0.81 | ACHE (0.49) | NOS3NOS1NOS2ACHEBCHE | |
| SCHEMBL16987421 | 0.79 | ACHE (0.47) | NOS3NOS1NOS2ACHEBCHE | |
| SCHEMBL527227 | 0.78 | NOS3 (0.64) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL29621658 | 0.78 | NOS3 (0.64) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL16871986 | 0.78 | ACHE (0.42) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL3467970 | 0.77 | ACHE (0.45) | NOS3NOS1NOS2ACHEBCHE | |
| SCHEMBL20417066 | 0.77 | NOS3 (0.62) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL30225174 | 0.77 | ACHE (0.45) | NOS3NOS1NOS2ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| WO-2006035967-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR TREATING DISEASES RELATED TO MCH RECEPTOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | MCHR1, GPR119, MCHR2 | NOS3 1226/4885NOS1 753/4885NOS2 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.